studies

la/mBC - HR-positive - 2nd line (L2), palbociclib based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsPALOMA-3, 2016 0.81 [0.64; 1.03] 0.81[0.64; 1.03]PALOMA-3, 201610%521NAnot evaluable progression or deaths (PFS)detailed resultsFLIPPER, 2021 0.55 [0.36; 0.84] PALOMA-3, 2016 0.42 [0.32; 0.56] 0.46[0.36; 0.59]FLIPPER, 2021, PALOMA-3, 2016210%710lownot evaluable objective responses (ORR)detailed resultsFLIPPER, 2021 2.90 [1.81; 4.64] 2.90[1.81; 4.64]FLIPPER, 202110%189NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-18 10:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1375,1249,1407,1376,1411

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons